Ovid Therapeutics Inc.

NASDAQ:OVID

Biotechnology

Healthcare
$2.34 -4.34%

-$0.11 today

Market cap
$441.63M
Beta
0.18
P/E (TTM)
-7.1
EPS (TTM)
-$0.33
52W Low $0.29High $3.11

Volume 1.77M

Average 3.07M

Returns on capital

Ovid Therapeutics Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-13.3%

avg -57.5%

ROIC

-29.5%

avg -57.7%

ROA

-11.5%

avg -42.9%

Analysis

ROA is currently the strongest return metric at -11.5% versus its period average of -42.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jeremy Max Levin Ba Zoology Dphil Mb Bchir

Co-Founder & Executive ChairmanUSD 1.19M73——

Margaret Alexander

CEO, President & DirectorUSD 879K45——

Jeffrey A. Rona

AdvisorUSD 825.89K58156.31K0.12%

Petra Kaufmann

Chief Medical Officer—60——

Kevin Norrett

Chief Business Officer—53——

Victoria Fort

Chief Strategy Officer————

Charles Ross Carter

CFO, Principal Financial Officer, Principal Accounting Officer & Secretary—5944.38K0.03%

Manal Morsy

Chief Regulatory Officer————

Julia Tsai

Senior Vice President of Clinical Development—51——

Toshiya Nishi

Head of Epilepsy Research————

Zhong Zhong

Chief Scientific Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

3

$115,966.20

Sells

2

$29,285.65

Net Transaction Value

+$86,680.55

Net buying

Most Active

LEVIN JEREMY M

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Feb 23, 26

ALEXANDER MARGARET A.

Direct

Sell$16.9K
Feb 23, 26

Rona Jeffrey A

Direct

Sell$12.4K
Dec 11, 25

LEVIN JEREMY M

Direct

Buy$0
Dec 11, 25

LEVIN JEREMY M

Direct

Buy$66.3K
Dec 11, 25

LEVIN JEREMY M

Direct

Buy$49.7K

Summary

Insiders reported 3 buys worth $115,966.20 and 2 sells worth $29,285.65 over the last 12 months. That adds up to net buying of $86,680.55. LEVIN JEREMY M was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A+69.0%
+52.5% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +69.0% over three years. Forward estimates point to Revenue at +52.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Ovid Therapeutics Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about OVID's management, answered from reported figures.

Who manages OVID?

Ovid Therapeutics Inc. (OVID) lists 11 active executives. The top listed executive is Petra Kaufmann, Chief Medical Officer.

Are OVID insiders buying or selling?

Recent insider activity shows net buying of $47.55M.